Faster AMR Drug Reviews And A New Pathogen List On Health Canada’s Agenda
Executive Summary
Health Canada is seeking comments on a proposed list of pathogens that is designed to help the government department understand how it can stimulate the submission of new drugs for beating antimicrobial resistance and facilitate their regulatory approval.
You may also be interested in...
Industry Welcomes EU’s Latest AMR Action Plan, But Public Health Advocates Remain Skeptical
The European Commission has unveiled its second action plan to tackle antimicrobial resistance, this time under the “one health” banner. This new initiative includes a set of guidelines for use by the EU member states when planning their anti-resistance strategies.
EU, US & Japan Tackle Difficulties With Randomized Trials Involving Multi-Drug Resistant Bacteria
The European Medicines Agency has given the Pink Sheet more detail on its recent agreement with its counterparts in the US and Japan to align certain clinical data requirement to stimulate the development of new treatments to fight antimicrobial resistance.
Why Still Nothing For AMR? EMA Asks PRIME Scheme Applicants
The European Medicines Agency wants AMR drug developers to apply for entry on its priority medicine (PRIME) scheme.